aTYR PHARMA INC Additional Paid in Capital, Common Stock
aTYR PHARMA INC (ATYR) had Additional Paid in Capital, Common Stock of $281.59 million as of 2017-06-30, per its 10-Q filed 2017-08-14.
Discontinued › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2017-08-14
- 2017-06-30: Additional Paid in Capital, Common Stock $281.59M.
- 2017-03-31: Additional Paid in Capital, Common Stock $280.13M.
- 2016-12-31: Additional Paid in Capital, Common Stock $278.83M.
- 2016-09-30: Additional Paid in Capital, Common Stock $277.37M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2017-06-30 | $281.59M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $280.13M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $278.83M 10-Q · filed 2017-08-14 |
| 2016-09-30 | $277.37M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $276.12M 10-Q · filed 2016-08-10 |
| 2016-03-31 | $274.64M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $273.32M 10-K · filed 2017-03-16 |
| 2015-09-30 | $270.83M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $269.73M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $21.21M 10-Q · filed 2015-06-18 |
| 2014-12-31 | $19.21M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |